Medpace Stock Price, News & Analysis (NASDAQ:MEDP)

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Medpace Holdings Inc (NASDAQ:MEDP) posted its quarterly earnings results on Monday, July, 29th. The company reported $0.81 EPS for the quarter, topping analysts' consensus estimates of $0.63 by $0.18. The company earned $214.10 million during the quarter, compared to analysts' expectations of $200.99 million. Medpace had a return on equity of 17.65% and a net margin of 11.28%. Medpace's revenue was up 25.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.61 EPS. View Medpace's Earnings History.

Medpace is scheduled to release their next quarterly earnings announcement on Monday, October 28th 2019. View Earnings Estimates for Medpace.

Medpace will be holding an earnings conference call on Monday, October 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Medpace issued an update on its FY19 earnings guidance on Monday, July, 29th. The company provided earnings per share guidance of $2.83-2.93 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.65. The company issued revenue guidance of $840-860 million, compared to the consensus revenue estimate of $827.58 million.

4 analysts have issued 12-month price objectives for Medpace's shares. Their predictions range from $62.00 to $85.00. On average, they expect Medpace's share price to reach $74.67 in the next twelve months. This suggests that the stock has a possible downside of 4.3%. View Analyst Price Targets for Medpace.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medpace.

Media headlines about MEDP stock have trended negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Medpace earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Medpace.

Medpace saw a decrease in short interest in September. As of September 15th, there was short interest totalling 2,320,000 shares, a decrease of 12.8% from the August 15th total of 2,660,000 shares. Based on an average trading volume of 407,200 shares, the days-to-cover ratio is currently 5.7 days. Approximately 8.5% of the shares of the company are sold short. View Medpace's Current Options Chain.

Some companies that are related to Medpace include Icon (ICLR), Charles River Laboratories Intl. (CRL), PRA Health Sciences (PRAH), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), National Research (NRC), Intrexon (XON), Auxly Cannabis Group (CBWTF), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), Luna Innovations (LUNA), Pieris Pharmaceuticals (PIRS) and Anavex Life Sciences (AVXL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include EXACT Sciences (EXAS), NVIDIA (NVDA), Alibaba Group (BABA), BioTelemetry (BEAT), Paypal (PYPL), Paycom Software (PAYC), Square (SQ), Cisco Systems (CSCO), Intuitive Surgical (ISRG) and ABIOMED (ABMD).

(MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

Medpace's stock is owned by a number of of retail and institutional investors. Top institutional investors include Scout Investments Inc. (0.27%), State of Alaska Department of Revenue (0.06%), Crossmark Global Holdings Inc. (0.02%) and We Are One Seven LLC (0.01%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Medpace Limited Partnership and Stephen P Ewald. View Institutional Ownership Trends for Medpace.

MEDP stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc. and Crossmark Global Holdings Inc.. Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger, Medpace Investors, Llc and Stephen P Ewald. View Insider Buying and Selling for Medpace.

MEDP stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue and We Are One Seven LLC. View Insider Buying and Selling for Medpace.

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MEDP stock can currently be purchased for approximately $78.04.

Medpace has a market capitalization of $2.80 billion and generates $704.59 million in revenue each year. The company earns $73.18 million in net income (profit) each year or $2.59 on an earnings per share basis. Medpace employs 2,900 workers across the globe.View Additional Information About Medpace.

The official website for Medpace is http://www.medpace.com/.

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]